Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Catherine Sims, MD DrCassySims
3 years 1 month ago
What if my patient with RA or PsA gets pregnant? @RheumNow #ACR22
Abstract #1786; 34 women
👶 Disease scores improved during #pregnancy and increased #postpartum
👶20-27% of women required a cesarean delivery
👶mean delivery 39-40 weeks gestation
👶 1 NICU admission https://t.co/qYPaB6TcDJ
David Liew drdavidliew
3 years 1 month ago
JAK inhibitors in RA: does their performance vary in the real world?
@opal_ltd 🇦🇺: n= 5900 JAKi-treated RA pts, 2015-2021
upa is relatively new in Australia, but amazing how bari and tofa are so similar
(same with the data on switching reason too)
ABST0274 #ACR22 @RheumNow https://t.co/63PrRVAzk5
Eric Dein ericdeinmd
3 years 1 month ago
Abst0328 #ACR22. Predicting UCTD to CTD Meta-Analysis
Factors for SLE transition: younger age, serositis, dsDNA
SSc transition: puffy finger, NFC, or SSc antibodies
No studies wo moderate or high risk of bias
Limited studies on biomarkers for SLE, need more studies
@Rheumnow https://t.co/GofGF8TkCx
sheila RHEUMarampa
3 years 1 month ago
Time check!⌚🦉
This roaming clockface helps me navigate through time zones while attending #ACR22
✈️virtually jetlagged but having fun!🤓
@RheumNow @rheumarhyme @doktora_ging #RheumPix https://t.co/HgTcIyw7ej
David Liew drdavidliew
3 years 1 month ago
Infections in JAKi v TNFi in RA
We've seen ORAL Surveillance data
What about East Asian pts, with enriched zoster risk?
National KOR🇰🇷 insurance data:
Bacterial: equal
Opportunistic: TNFi worse
Zoster: JAKi worse
serious zoster a lot more common here!
ABST0302 #ACR22 @RheumNow https://t.co/lxsbY1Nf9N
TheDaoIndex KDAO2011
3 years 1 month ago
“Conflict, crisis and resolution make a story. A good story has drama where there is desire with danger.” @cuttingforstone author, Dr. Verghese noted the COVID19 #pandemic has all of these elements. It is a good story, but we don’t know the resolution. @Rheumnow #ACR22 https://t.co/Tomev2SYcT
Dr. John Cush RheumNow
3 years 1 month ago
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its Faculty.
A new treatment for AxSpA that has come on the scene are JAK inhibitors. In clinic, considerations for JAKi use are body mass index, smoking status, prior use of biologics and patients with high inflammatory states such as high CRP and inflammatory change on MRI scan of the spine and sacroiliac joints. There are further studies at #ACR22 which help answer these questions.
A Japanese large scale claims data study was able to collect 5-year data to study the treatment patterns in Still’s. In May 2019, intravenous tocilizumab was approved in Japan for Still’s disease. The study was designed to see patterns of steroid exposure before and after the approval of this therapy.
Eric Dein ericdeinmd
3 years 1 month ago
Let’s do this #ACR22
@RheumNow #rheumpix https://t.co/zTx4TynK44
Dr. John Cush RheumNow
3 years 1 month ago
AS, Lupus and Subclinical RA: What I'm looking forward to at #ACR22
There are three areas that always draw my attention each conference and this time is no different...
https://t.co/1h7NRgcqCm https://t.co/9P1UwrmjxW
Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease.
Despite a wealth of treatment options, a number of notable unmet needs remain in PsA, most notably the significant diagnostic delay that many patients endure. We are all aware that those with psoriatic skin disease are the most at risk cohort for PsA. Identifying patients with psoriasis who have, or are at increased risk of PsA, appears to be the low hanging fruit that we just can’t fully seem to grasp.
The COVID-19 pandemic has had a significant impact worldwide particularly among those who are immunocompromised. Numerous studies have highlighted the increased risk of acute SARS-CoV-2 infection among patients with rheumatic diseases (RD). Public health measures including masking, social distancing, and vaccination have helped to lower the risk of acute SARS-CoV-2 infection in this population.
Poster Hall